CureVac NV (CVAC)vsModerna Inc (MRNA)
CVAC
CureVac NV
$4.66
0.00%
HEALTHCARE · Cap: $1.05B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 3050% more annual revenue ($2.23B vs $70.74M). CVAC leads profitability with a 182.1% profit margin vs -141.4%. CVAC earns a higher WallStSmart Score of 56/100 (C).
CVAC
Buy56
out of 100
Grade: C
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.5%
Fair Value
$12.42
Current Price
$4.66
$7.76 discount
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 182 of every $100 in revenue as profit
Strong operational efficiency at 573.0%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 89.0%
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CVAC
The strongest argument for CVAC centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 182.1% and operating margin at 573.0%.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : CVAC
The primary concerns for CVAC are Market Cap, Revenue Growth.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CVAC profiles as a declining stock while MRNA is a turnaround play — different risk/reward profiles.
CVAC carries more volatility with a beta of 1.84 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
CVAC generates stronger free cash flow (30M), providing more financial flexibility.
Bottom Line
CVAC scores higher overall (56/100 vs 21/100), backed by strong 182.1% margins. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CureVac NV
HEALTHCARE · BIOTECHNOLOGY · USA
CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?